Acceleron Pharma — Investor Presentation (January 2015)
68 slides from Acceleron Pharma's investor presentation, Jan 12, 2015
Slide 1: Corporate Overview January 2015
Page 0 Corporate Overview January 2015
Slide 2: Forward-Looking Statements
Page 1 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our bu
Slide 3: The Mission of Acceleron Pharma
Page 2 The Mission of Acceleron Pharma Acceleron will be a leader in the discovery, development and commercialization of therapeutics based on the body’s ability to regulate the growth and repair of its cells and tissues. By leveraging this powerful biology, Acceleron seeks to provide medicines that
Slide 4: Leader in protein therapeutics that regulate cellular growth and repair
Page 3 Acceleron is a leader in discovering and developing protein therapeutics that regulate cellular growth and repair Tissue Growth and Repair is Central to Human Disease and Health • Disease is often caused by either • Failure of cells or tissues to properly grow, differentiate and maintain the
Slide 5: Leader in Cell and Tissue Growth and Repair
Page 4 Red Blood Cells Acceleron – Leader in Cell and Tissue Growth and Repair Red Blood Cells Bone Vasculature Increases number of red blood cells Luspatercept Sotatercept Dalantercept Increases bone mass and strength, and RBC number Inhibits blood vessel growth Muscle ACE-083 Increases muscle mass
Slide 6: One of the Industry's Most Robust Pipelines of Internally Discovered Protein Therapeutics
Page 5 Acceleron -- One of the Industry’s Most Robust Pipelines of Internally Discovered Protein Therapeutics Creating Near-term and Sustainable Value Product Indication Development Stage Commercial Rights Luspatercept β-Thalassemia Phase 3 to start in 2015 • Co-development • North American co-promo
Slide 7: Highly Productive 2014 Sets Stage for 2015 Value Creation
Page 6 Highly Productive 2014 Sets Stage for 2015 Value Creation Demonstrated phase 3-enabling data in MDS Demonstrated phase 3-enabling data in beta-thalassemia Demonstrated proof-of-concept on bone density and vascular calcification in ESRD patients Advanced exploratory phase 2 studies in
Slide 8: Hematology Franchise: Luspatercept and Sotatercept
Page 7 Hematology Franchise Luspatercept and Sotatercept
Slide 9: Myelodysplastic Syndromes (MDS)
Page 8 Myelodysplastic Syndromes (MDS)
Slide 10: MDS Opportunity: Develop Better Treatment for Lower Risk Patients
Page 9 MDS Opportunity: Develop Better Treatment for Lower Risk Patients In the U.S., recombinant erythropoietin sales in MDS are approximately $600 million EPO MDS (125,000 patients in US/EU-G5)) Low Risk (70,000 patients US/EU-G5) High Risk (55K patients) RBC transfusions (± iron chelation) Revlim
Slide 11: MDS Program Highlights
Page 10 MDS Program Highlights • Luspatercept data in Myelodysplastic Syndromes selected for "Best of ASH" by the American Society of Hematology • Preliminary Phase 2 results demonstrated – Increases in hemoglobin levels – Decreases in transfusion burden with patients becoming transfusion independen
Slide 12: MDS Development Plan: Initiate Phase 3 in 2015
Page 11 MDS Development Plan: Initiate Phase 3 in 2015 Q1 Q2 Q3 Q4 Confirm dose-titration in expansion cohort (n=30) Health Authority meetings re: Phase 3 Initiate Phase 3 trials 2015 Q3 Q4 2014 Completed dose escalation cohorts (n=27)
Slide 13: MDS Phase 3 Development Opportunities
Page 12 MDS Phase 3 Development Opportunities EPO Low Risk MDS (70,000 patients US/EU-G5) Revlimid® Vidaza® Dacogen® 2nd Line Opportunity: ESA experienced patients • Endpoint: Incidence of RBC Transfusions • Randomized vs. best supportive care 1st Line Opportunity: ESA naïve patients • Endpoint: Inc
Slide 14: B-thalassemia
B-thalassemia =! =" = ACCELERON
Slide 15: Beta-Thalassemia Opportunity
Page 14 Beta-Thalassemia Opportunity: Develop Treatment for Both Non-Transfusion and Transfusion Dependent Patients Beta-Thalassemia (40,000 patients in US/EU) Non-Transfusion Dependent (20,000 patients US/EU) Transfusion Dependent (20,000 patients US/EU) RBC transfusions (iron chelation used to man
Slide 16: Beta-Thalassemia Program Highlights
Page 15 Beta-Thalassemia Program Highlights • Preliminary Phase 2 results demonstrated – Activity in both non-transfusion and transfusion dependent patients that met/exceeded endpoints expected to be used in phase 3 trials • Increases in hemoglobin levels • Decreases in transfusion burden • Reductio
Slide 17: Beta-Thalassemia Development Plan: Initiate Phase 3 in 2015
Page 16 Beta-Thalassemia Development Plan: Initiate Phase 3 in 2015 Q1 Q2 Q3 Q4 Confirm dose-titration in expansion cohort (n=30) Health Authority meetings re: Phase 3 Initiate Phase 3 trials 2015 Q3 Q4 2014 Completed dose escalation cohorts (n=30)
Slide 18: Beta-Thalassemia Phase 3 Program
Page 17 Beta-Thalassemia Phase 3 Program Beta-Thalassemia (40K patients in US/EU) Non-Transfusion Dependent (20,000 patients US/EU) Transfusion Dependent (20,000 patients US/EU) Phase 3 – NTD Patients • Endpoints • Primary: hemoglobin increase ≥ 1.5 g/dL • Secondary: decreases in iron overload • Ran
Slide 19: Sotatercept Opportunity in Chronic Kidney Disease
Page 18 Sotatercept Opportunity in Chronic Kidney Disease
Slide 20: ESRD Opportunity: Novel Drug for Bone Loss and Vascular Calcification
Page 19 ESRD Opportunity: Develop Fundamentally Novel Drug to Treat Bone Loss and Vascular Calcification ESRD patients on hemodialysis (700,000 patients in US/EU) Vascular Calcification Bone Loss Epidemiology Current Treatments Therapeutic Goal • Increase bone mineral density • Reduce vascular calci
Slide 21: ESRD Program Highlights
Page 20 ESRD Program Highlights • Preliminary sotatercept Phase 2 results demonstrated – Increases in cortical bone mineral density – Reductions in vascular calcification – Increases in hemoglobin levels • 2015 program goals – Complete ongoing Phase 2a study – Compete dose finding stage of ongoing P
Slide 22: ESRD Development Plan
Page 21 ESRD Development Plan Q1 Q2 Q3 Q4 Phase 2b - dose finding stage (n=~60) 2015 Q3 Q4 2014 Phase 2a study (n=~48) Phase 2b - randomized, placebo-controlled stage (n=230)
Slide 23: Muscle Franchise: ACE-083
Page 22 Muscle Franchise ACE-083
Slide 24: ACE-083 Doubles Muscle Mass in Injected Muscle After One Month
Page 23 ACE-083 Doubles Muscle Mass Selectively in Injected Muscle After One Month of Treatment 0.0000 0.0020 0.0040 0.0060 0.0080 0.0100 0.0120 0.0140 Left Right Gastroc Ga st roc W eig h t N o rm ali ze d t o B o d y W eig h t PBS ACE-083 1μg ACE-083 3μg ACE-083 10μg ACE-083 30μg ACE-083 100μg ACE
Slide 25: MRI Imaging of Muscle and Fat to Demonstrate Changes
Page 24 MRI Imaging of Muscle and Intramuscular and Subcutaneous Fat Will be Used to Demonstrate Changes in Muscle Size and Composition SC Fat Muscle IM Fat Grey = Muscle Pink = SC fat Green = IM fat
Slide 26: Potential Clinical Indications For ACE-083
Page 25 Affected Muscle Groups in Muscle Wasting Diseases Potential Clinical Indications For ACE-083 Facioscapulohumeral Muscular Dystrophy (16,000 patients – US) Inclusion Body Myositis (11,000 patients – US) Muscular Dystrophy Association USA
Slide 27: ACE-083 Development Plan
Page 26 ACE-083 Development Plan: Initiate Phase 2 Studies in 2015 Q1 Q2 Q3 Q4 2015 Q3 Q4 2014 Phase 1 study (n=40) Phase 2 study
Slide 28: Dalantercept
Page 27 Dalantercept Novel anti-angiogenic agent based on the Activin Receptor-Like Kinase 1 (ALK1)
Slide 29: Dalantercept Opportunity in RCC and HCC
Page 28 Dalantercept Opportunity in RCC and HCC Renal Cell Carcinoma (65,000 new patients/year in US) Chemo, TACE Epidemiology Current Treatments VEGFR TKIs mTOR inhibitors Hepatocellular Carcinoma (31,000 new patients/year in US) • More than 70% of all RCC patients currently receive an anti-VEGF dr
Slide 30: Dalantercept + anti-VEGF Development Plan
Page 29 Dalantercept + anti-VEGF Development Plan Q1 Q2 Q3 Q4 Randomized, placebo-controlled stage (n=130) RCC (+ axitinib) HCC (+ sorafenib) HCC(+ sorafenib) 2015 Q3 Q4 2014 RCC (+ axitinib) Completed dose escalation cohorts (n=29) Dose escalation cohorts Dose expansion cohort
Slide 31: Financial Highlights
Page 30 Financial Highlights • Cash and cash equivalents at the end of September 2014 were $189 million • Cash and cash equivalents expected to provide the Company funding for three years into the second half of 2017
Slide 32: Anticipated Data Presentations in 2015
Page 31 Anticipated Data Presentations in 2015 Program Indication Date / Meeting Dalantercept RCC February; ASCO-GU Luspatercept MDS April; MDS Int’l Symposium June; EHA December; ASH Beta-thalassemia June; EHA December; ASH ACE-083 Muscle October; World Muscle Society Sotatercept ESRD May; ERA-EDTA
Slide 33: Poised for Significant Value Creation in 2015
Page 32 Poised for Significant Value Creation in 2015 Complete phase 2 studies in MDS and beta-thalassemia Finalize phase 3 development plans with health authorities for MDS and beta-thalassemia Initiate phase 3 clinical trials in MDS Initiate phase 3 clinical trials in beta-thalassemia In
Slide 34: Acceleron's 2020 Vision
Page 33 • Two Phase 3 studies • Six Phase 2 studies • One Phase 1 study • 4 protein therapeutics in clinical trials • Numerous preclinical programs • Approvals in up to 5 indications • Multiple Phase 3 studies • 8 protein therapeutics in clinical trials • Sales and marketing organization in U.S. • C
Slide 35: Additional Information
Page 34 Additional Information
Slide 36: Myelodysplastic Syndromes (MDS) Presented at ASH 2014
Page 35 Myelodysplastic Syndromes (MDS) Presented at ASH 2014
Slide 37: Luspatercept PACE-MDS Study Design
Page 36 Luspatercept PACE-MDS Study Design Cohort 7 1.75 mg/kg (N=3) Cohort 5 1.0 mg/kg (N=3) Cohort 6 1.33 mg/kg (N=6) Cohort 1 0.125 mg/kg (N=3) Cohort 2 0.25 mg/kg (N=3) Cohort 3 0.5 mg/kg (N=3) Cohort 4 0.75 mg/kg (N=6) 3 Months Treatment Expansion Cohort Individually titrated dose (N=30) Data a
Slide 38: Baseline Characteristics
Page 37 Baseline Characteristics All Patients N = 26 Age, yr, median (range) 71 (27-88) Sex, males (%) 13 (50%) Prior ESA treatment, n (%) 14 (54%) Prior lenalidomide treatment, n (%) 5 (19%) Low Transfusion Burden (LTB) N = 7 (27%) Hemoglobin, g/dL, median (range) 9.1 (8.3-9.7) Units RBC/8 weeks, m
Slide 39: Pharmacokinetic and Safety Summary
Page 38 Pharmacokinetic and Safety Summary Pharmacokinetics Dose-dependent increase in Cmax and area under curve (AUC) Mean half-life (t½) is approximately 14 days, supporting Q3W dosing Safety No drug-related serious adverse events (AEs) One possibly related grade 3 AE of blast cell count i
Slide 40: Luspatercept Increased Hemoglobin and Reduced Transfusions in Lower Risk MDS
Page 39 Patient Subgroup 0.125-0.5 mg/kg (N=9) n (%) 0.75-1.75 mg/kg (N=17) n (%) LTB patients (N=7) 0/2 (0%) 2/5 (40%) HTB patients (N=19) 2/7 (29%) 5/12 (42%) All patients (N=26) 2/9 (22%) 7/17 (41%) HI-E (IWG): LTB: Hemoglobin increase ≥1.5 g/dL for ≥8 weeks HTB: Reduction of ≥4 units RBCs transf
Slide 41: Luspatercept Produced Dose Dependent Increases in LTB Patients
Page 40 Data as of 03 Oct 2014 LTB, low transfusion burden M ean ( SD ) M ax. C h an ge in H emogl o b in ( g/ d L) 0.8 1.0 2.2 3.5 0.0 1.0 2.0 3.0 4.0 0.125 (n=1) 0.25 (n=1) 0.75 (n=3) 1.75 (n=2) Dose Group (mg/kg) Luspatercept Produced Dose Dependent Increases in LTB Patients Luspatercept MDS Phas
Slide 42: Luspatercept Increased and Maintained Hemoglobin in LTB Patients
Page 41 Response Criteria 0.125-0.5 mg/kg N=2 n (%) 0.75-1.75 mg/kg N=5 n (%) Hemoglobin increase ≥1.5 g/dL for ≥2 weeks 0 4 (80%) Hemoglobin increase ≥1.5 g/dL for ≥8 weeks (HI-E) 0 2 (40%) • All 5 patients at the higher dose levels had prior ESA treatment • No patients received prior lenalidomide
Slide 43: Luspatercept Activity in a LTB Patient
Page 42 Hemoglobin ( g /d L) Weeks -- 0.56 mg/kg (dose reduced by 25%) Data as of 03 Oct 2014 LTB, low transfusion burden 2 0 1 2 3 4 5 6 7 8 6 7 8 9 10 11 12 13 -8 -6 -3 BL 3 6 9 12 16 20 24 Units Transfused Hemoglobin Follow-up Period Dose held for Hb >12 g/dL -- 0.75 mg/kg (starting dose) 78 year
Slide 44: Luspatercept Reduced Transfusions in HTB Patients
Page 43 HTB, high transfusion burden • 9/19 (47%) of patients received prior ESA treatment • 5/19 (26%) of patients received prior lenalidomide treatment RBC Transfusion Reduction over 8 Weeks 0.125-0.5 mg/kg N=7 n (%) 0.75-1.75 mg/kg N=12 n (%) ≥4 Units or ≥50% 3 (43%) 5 (42%) ≥4 Units (HI-E) 2 (29
Slide 45: Luspatercept Activity in a HTB Patient
Page 44 Weeks Data as of 03 Oct 2014 HTB, high transfusion burden Hemoglobin ( g /d L) Follow-up Period 2 2 0 2 4 6 8 10 12 5 6 7 8 9 10 11 -3 BL 3 6 9 12 16 20 24 Units Transfused Hemoglobin 0.75 mg/kg (starting dose) 71 year old female RCMD-RS Failed LEN, EPO Luspatercept Activity in a HTB Patient
Slide 46: Response Rates by Ring Sideroblast Morphology, SF3B1 Mutation
Page 45 Data as of 03 Oct 2014 Baseline Status Response Rate (HI-E) n (%) All Patients (N=17) 7 (41%) Ring Sideroblasts RS ≥15% (N=13) 7 (54%) RS <15% (N=4) 0 (0%) Response Rate at Higher Dose Levels (0.75-1.75 mg/kg) * All 9 patients with SF3B1 mutation present had RS ≥15% ** Includes all 3 patient
Slide 47: β-thalassemia Presented at ASH 2014
Page 46 β-thalassemia Presented at ASH 2014
Slide 48: β-thalassemia: Rare Hematologic Disease with Substantial Unmet Medical Need
Page 47 Bone deformity, fractures and bone pain Iron overload, liver and heart failure Enlarged spleen, blood clots and ulcerations Chronic anemia β-thalassemia: Rare Hematologic Disease with Substantial Unmet Medical Need Beta-Thalassemia is red blood cell (RBC) disease Substantial unmet medical ne
Slide 49: Study Overview: Luspatercept β-Thalassemia Phase 2 Trial
Page 48 Study Overview Luspatercept -Thalassemia Phase 2 Clinical Trial NCT01749540, EudraCT 2012-002499-15 • A phase 2, multicenter, open-label, dose escalation study in adults with β-thalassemia • Primary efficacy endpoints: • Non-transfusion dependent (NTD)* Hb increase of ≥ 1.5 g/dL for ≥ 2 w
Slide 50: Study Design: Luspatercept β-Thalassemia Phase 2 Trial
Page 49 Study Design Luspatercept -Thalassemia Phase 2 Clinical Trial Cohort 5 1.0 mg/kg (N=6) Cohort 1 0.2 mg/kg (N=6) Cohort 2 0.4 mg/kg (N=6) Cohort 3 0.6 mg/kg (N=6) Cohort 4 0.8 mg/kg (N=6) 3 Months Treatment Completed Data from completed cohorts presented Cohort 6 1.25 mg/kg (N=6) Expansion C
Slide 51: Baseline Characteristics
Page 50 Baseline Characteristics Luspatercept -Thalassemia Phase 2 Clinical Trial All Patients N=30 Age, yr, median (range) 34.5 (20-57) Sex, male (%) 16 (53%) Splenectomy (%) 25 (83%) Non-Transfusion Dependent (NTD) N= 23 (77%) Hemoglobin, g/dL, mean ± SD 8.3 ± 0.9 Transfusion Dependent (TD) N=7 (
Slide 52: Safety Summary
Page 51 Safety Summary Luspatercept -Thalassemia Phase 2 Clinical Trial • No related serious adverse events – 1 grade 3 dose-limiting toxicity (worsening lumbar spine bone pain) • 3 patients discontinued early associated with an AE – 1 each with occipital headache, ankle pain, and back pain Data as
Slide 53: Luspatercept Increased Hemoglobin and Reduced Transfusions
Page 52 Luspatercept Increased Hemoglobin and Reduced Transfusions Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 75% of patients treated with 0.8-1.0 mg/kg met the primary endpoint for efficacy 0.2-0.6 mg/kg (N=18) n (%) 0.8-1.0 mg/kg (N=12) n (%) NTD Patients (N=23): Hemo
Slide 54: Reduced Transfusion Burden in TD Patients
Page 53 Reduced Transfusion Burden in TD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial -100 -80 -60 -40 -20 0 -79% -67% -70% -75% -63% -67% -100% • 7/7 (100%) patients had >60% reduction in transfusion burden over 12 weeks • Includes 2 patients with β0β0 genotype (79%, 75% reduction) TD
Slide 55: Maximum Hemoglobin Increase in NTD Patients
Page 54 NTD, Non-transfusion dependent Maximum Hemoglobin Increase in NTD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014
Slide 56: NTD Responder Hemoglobin
Page 55 NTD Responder Hemoglobin Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 NTD, Non-transfusion dependent He m og lo bi n (g /d L) Weeks 0 1 2 3 4 5 6 7 8 6 7 8 9 10 11 -3 BL 3 6 9 12 16 20 Hemoglobin 0.8 mg/kg 24 year old male Splenectomized Follow-up Period
Slide 57: Liver Iron Concentration in NTD Patients
Page 56 Liver Iron Concentration (LIC by MRI) in NTD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 Baseline LIC ≥ 5 mg/g dry weight (dw) (n=12) • 8/12 patients had a decrease of ≥1 mg/g dw -5 -4 -3 -2 -1 0 1 2 3 On iron chelator No iron chelator C h an ge f ro m B
Slide 58: Healing of Leg Ulcers in Patients
Page 57 Healing of Leg Ulcers in 2 of 2 Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Pre-Treatment After 6 Weeks Pre-Treatment After 4 Weeks After 18 Weeks TD patient treated at 1.0 mg/kg NTD patient treated at 0.4 mg/kg NTD, Non-transfusion dependent TD, Transfusion dependent Data as
Slide 59: Sotatercept Opportunity in Chronic Kidney Disease
Page 58 Sotatercept Opportunity in Chronic Kidney Disease
Slide 60: Chronic Kidney Disease Mineral and Bone Disorder
Page 59 Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) End-Stage Renal Disease Anemia Nearly all end-stage renal disease patients on dialysis suffer from anemia and mineral and bone disorder Mineral and Bone Disorder Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism Abno
Slide 61: Sotatercept Improved Bone Metabolism
Page 60 • Unlike age-related osteoporosis, in CKD-related bone disease there can be – Increase in trabecular bone mass and a decrease in cortical bone mass • Sotatercept data presented at the 2014 ASN Kidney Week showed dose-dependent – Decreases in trabecular bone mass – Increases in cortical bone
Slide 62: Vascular Calcification in ESRD Patients
Page 61 • Two types of vascular calcification - intimal (atherosclerotic) and medial • Both associated with osteoblastic transition of vascular smooth muscle cells • Medial calcification more common in ESRD patients • Vascular calcification is the strongest measure in cardiovascular risk prediction
Slide 63: Sotatercept Substantially Slowed Vascular Calcification
Page 62 Sotatercept Substantially Slowed Vascular Calcification Sotatercept Phase 2 Clinical Trial in ESRD Patients 58.4% 24.9% 17.3% 3.4% 0 10 20 30 40 50 60 70 Placebo 0.3 mg/kg 0.5 mg/kg 0.7 mg/kg Change in Agatston Score Over 8 Months Agatston score is a standard measure of vasculature calcifica
Slide 64: Dalantercept (ACE-041)
Page 63 Dalantercept (ACE-041) Novel anti-angiogenic agent based on the Activin Receptor-Like Kinase 1 (ALK1)
Slide 65: BMP9/ALK1 Pathway: Novel Target for Angiogenesis
Page 64 BMP9/ALK1 Pathway: Novel Target for Angiogenesis • ALK1 is selectively expressed on vascular and lymphatic endothelial cells • In mice, homozygous deletion of ALK1 (-/-) results in severe vascular defects and embryonic lethality • Patients with hereditary hemorrhagic telangiectasia (HHT-2) h
Slide 66: Dalantercept Combination Development Strategy
Page 65 Dalantercept Combination Development Strategy: Inhibit Two Key Steps in Angiogenesis to Improve Clinical Outcomes Concept: Inhibit sequential steps in pathway to augment angiogenic blockade Proliferation VEGF Receptor Maturation ALK1 Receptor Mature blood vessel supporting tumor growth
Slide 67: Positive Results from Part 1 RCC Ph2 Study
Page 66 Positive Results from Part 1 RCC Ph2 Study dalantercept + axitinib (presented at ASCO 2014) • Dalantercept combination therapy was well-tolerated and no dose-limiting toxicities were observed in the dose escalation cohorts • Encouraging preliminary efficacy of dalantercept: – Combination ach
Slide 68: Dalantercept Vision: Improve and Extend Response Rates
Page 67 IntrinsIQ (Diag Drug LOT Yearly Kidney Cancer April 2014), Evaluate Pharma By combining with established practice of using anti-VEGF therapies, dalantercept can quickly access a large segment of both the RCC and HCC markets Dalantercept Vision: Improve and Extend Response Rates • Worldwide s
Acceleron Pharma — Investor Presentation (January 2015) on 6ix